Publications by authors named "D Darmoul"
Article Synopsis
- - The study aimed to evaluate how the serine protease KLK6 affects colorectal cancer development in mice with a mutant tumor suppressor gene, finding that KLK6 expression increases significantly in tumors compared to normal tissue.
- - Techniques like immunohistochemistry confirmed KLK6 presence, and genetically altered mice lacking KLK6 showed smaller tumor sizes and fewer adenomas, indicating KLK6's crucial role in tumor growth.
- - The research highlights KLK6 as an important factor for intestinal tumorigenesis, suggesting it could be useful for early diagnosis of colorectal cancer.
Kallikrein-related peptidases (KLKs) are implicated in many cancer-related processes. KLK6, one of the 15 KLK family members, is a promising biomarker for diagnosis of many cancers and has been associated with poor prognosis of colorectal cancer (CRC) patients. Herein, we evaluated the expression and cellular functions of KLK6 in colon cancer-derived cell lines and in clinical samples from CRC patients.
View Article and Find Full Text PDFColorectal cancer (CRC) remains one of the leading causes of cancer-related death worldwide. The high mortality of CRC is related to its ability to metastasize to distant organs. The kallikrein-related peptidase Kallikrein 6 (KLK6) is overexpressed in CRC and contributes to cancer cell invasion and metastasis.
View Article and Find Full Text PDFThe activity of kallikrein-related peptidase 6 (KLK6) is deregulated in various diseases such as cancer and neurodegenerative diseases. KLK6 is thus considered as an attractive therapeutical target. In this short report, we depict some novel findings on the regulation of the KLK6 activity.
View Article and Find Full Text PDFPurpose: Gene expression of a variety of the 15 members of the KLK serine protease family is dysregulated in ovarian cancer. We aimed at determining the clinical relevance of KLK13 and KLK14 mRNA expression in tumor tissues of a homogeneous patient cohort afflicted with advanced high-grade serous ovarian cancer (FIGO stage III/IV).
Methods: mRNA expression levels of KLK13 and KLK14 were assessed by quantitative PCR in tumor tissue of 91 patients and related with clinical factors and patients' outcome.